Actionability = is there something to do. Prevalence = how much of a general GI practice it touches. Stakes = how consequential the decision is. Evidence strength = how far the study design and the result support the action. Novelty = how likely you are not already doing it.
IBDrct · n=600 · Oct 27, 2026 · Clin Gastro Hep · IF 16.2
New evidenceCrohn's diseasebiologicstherapeutic drug monitoring
Clinical takeawayConsider SC guselkumab induction as an equally effective alternative to IV induction for moderately to severely active Crohn's disease, given similar efficacy and safety profiles, with adverse events comparable to placebo.
What it foundIV and SC guselkumab induction were equally effective for moderately to severely active Crohn's disease, with 39.5-51.2% achieving deep remission at Week 96 compared to placebo.
ContextConfirms that SC induction is non-inferior to IV induction for guselkumab in moderately to severely active Crohn's disease, aligning with current practice favoring SC administration for convenience.
Measured against the standard of care· ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH)ShowHide
No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.
Our full summary of this standardShowHide
Two current US guidelines govern Crohn's disease and should be read together. ACG 2025 (Lichtenstein et al.) remains the reference for diagnosis, mild-to-moderate disease, perianal, postoperative and abscess management. DIAGNOSIS: fecal calprotectin (>50-100 μg/g) separates inflammatory from noninflammatory disease of the colon. Workup is ileocolonoscopy with biopsies, including uninvolved mucosa, plus small-bowel imaging. CTE and MRE are comparable; prefer MRE in patients <35 y and when serial exams are likely. Intestinal ultrasound is an ungraded adjunct. Do routine CRC surveillance in Crohn's colitis. MILD-TO-MODERATE: recommend against oral mesalamine; sulfasalazine only for symptomatic mild colonic CD; ileal-release budesonide 9 mg for induction in ileocecal disease but not for maintenance. MODERATE-TO-SEVERE (AGA Living Guideline, Scott et al., Gastroenterology 2025;169(7):1397-1448, 16 recommendations: 1 strong, 9 conditional, 6 knowledge gaps; updated quarterly, adult outpatients only): RECOMMEND infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab or upadacitinib over no treatment; SUGGEST certolizumab pegol or vedolizumab over no treatment. Advanced-therapy-naive: suggest higher-efficacy agents (infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, guselkumab) over lower-efficacy ones (certolizumab pegol, upadacitinib). Prior advanced-therapy (especially anti-TNF) exposure: suggest higher- or intermediate-efficacy agents (adalimumab, risankizumab, guselkumab, upadacitinib; ustekinumab, mirikizumab) over lower-efficacy ones (vedolizumab, certolizumab pegol). Suggest against thiopurine monotherapy for induction; suggest it for maintenance of remission. Suggest SC/IM methotrexate monotherapy; suggest against oral methotrexate. In thiopurine-naive patients starting infliximab, suggest infliximab + thiopurine over infliximab alone. No recommendation on IFX + MTX, adalimumab + immunomodulator, or non-TNF biologic + immunomodulator. After ≥6 months of steroid-free remission on anti-TNF + immunomodulator, suggest withdrawing the immunomodulator and suggest against withdrawing the anti-TNF. SUGGEST upfront advanced therapy over step-up therapy (corticosteroids and/or immunomodulator first). No recommendation on treating to endoscopic vs symptomatic remission. The ACG 2025 moderate-to-severe recommendations (anti-TNF, IFX + thiopurine combination and IL-12/23/IL-23 agents, each strong/moderate; upadacitinib after anti-TNF exposure; steroids for short-term induction only; TPMT/NUDT15 testing before thiopurines) still stand alongside AGA. ACG perianal (infliximab first; drain abscesses and place setons before escalating), postoperative (endoscopy at 6-12 months; anti-TNF strong, vedolizumab conditional in high-risk patients) and intra-abdominal abscess (>2 cm: antibiotics plus drainage, hold immunosuppression) positions are unchanged. THERAPEUTIC ENDOSCOPY (AGA Clinical Practice Update, CGH 2026; details below come from AGA news coverage, not the full text, and are ungraded advice): get cross-sectional imaging before the procedure. Endoscopic balloon dilation is first-line for short strictures (about ≤4-5 cm) with few risk factors (fistula, prestenotic dilation >5 cm, high CRP, prior anti-TNF). Longer or multiple strictures, or ≥3 risk factors, favor surgery.
D'Haens GR … Sands BE · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
IBDmeta analysis · Nov 1, 2026 · Inflamm Bowel Dis · IF 4.5
New evidenceCrohn's diseasebiologicsJAK inhibitorsperianal disease
Clinical takeawayEvidence is strongest for infliximab; data for adalimumab, ustekinumab and upadacitinib are limited and mostly post hoc analyses of luminal trials with moderate to serious risk of bias.
What it foundAcross 14 placebo-controlled studies (only 4 designed for perianal disease), advanced therapies improved induction fistula response (RR 1.65) and remission (RR 1.91), and maintenance response (RR 1.54) and remission (RR 2.08). Infliximab and upadacitinib improved response and remission in induction, and infliximab also in maintenance.
ContextNo head-to-head or line-of-therapy comparisons were made.
Measured against the standard of care· ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH)ShowHide
…MILD-TO-MODERATE: recommend against oral mesalamine; sulfasalazine only for symptomatic mild colonic CD; ileal-release budesonide 9 mg for induction in ileocecal disease but not for maintenance.…Advanced-therapy-naive: suggest higher-efficacy agents (infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, guselkumab) over lower-efficacy ones (certolizumab pegol, upadacitinib).…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text. The rest of this standard includes DIAGNOSIS.
Our full summary of this standardShowHide
Two current US guidelines govern Crohn's disease and should be read together. ACG 2025 (Lichtenstein et al.) remains the reference for diagnosis, mild-to-moderate disease, perianal, postoperative and abscess management. DIAGNOSIS: fecal calprotectin (>50-100 μg/g) separates inflammatory from noninflammatory disease of the colon. Workup is ileocolonoscopy with biopsies, including uninvolved mucosa, plus small-bowel imaging. CTE and MRE are comparable; prefer MRE in patients <35 y and when serial exams are likely. Intestinal ultrasound is an ungraded adjunct. Do routine CRC surveillance in Crohn's colitis. MILD-TO-MODERATE: recommend against oral mesalamine; sulfasalazine only for symptomatic mild colonic CD; ileal-release budesonide 9 mg for induction in ileocecal disease but not for maintenance. MODERATE-TO-SEVERE (AGA Living Guideline, Scott et al., Gastroenterology 2025;169(7):1397-1448, 16 recommendations: 1 strong, 9 conditional, 6 knowledge gaps; updated quarterly, adult outpatients only): RECOMMEND infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab or upadacitinib over no treatment; SUGGEST certolizumab pegol or vedolizumab over no treatment. Advanced-therapy-naive: suggest higher-efficacy agents (infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, guselkumab) over lower-efficacy ones (certolizumab pegol, upadacitinib). Prior advanced-therapy (especially anti-TNF) exposure: suggest higher- or intermediate-efficacy agents (adalimumab, risankizumab, guselkumab, upadacitinib; ustekinumab, mirikizumab) over lower-efficacy ones (vedolizumab, certolizumab pegol). Suggest against thiopurine monotherapy for induction; suggest it for maintenance of remission. Suggest SC/IM methotrexate monotherapy; suggest against oral methotrexate. In thiopurine-naive patients starting infliximab, suggest infliximab + thiopurine over infliximab alone. No recommendation on IFX + MTX, adalimumab + immunomodulator, or non-TNF biologic + immunomodulator. After ≥6 months of steroid-free remission on anti-TNF + immunomodulator, suggest withdrawing the immunomodulator and suggest against withdrawing the anti-TNF. SUGGEST upfront advanced therapy over step-up therapy (corticosteroids and/or immunomodulator first). No recommendation on treating to endoscopic vs symptomatic remission. The ACG 2025 moderate-to-severe recommendations (anti-TNF, IFX + thiopurine combination and IL-12/23/IL-23 agents, each strong/moderate; upadacitinib after anti-TNF exposure; steroids for short-term induction only; TPMT/NUDT15 testing before thiopurines) still stand alongside AGA. ACG perianal (infliximab first; drain abscesses and place setons before escalating), postoperative (endoscopy at 6-12 months; anti-TNF strong, vedolizumab conditional in high-risk patients) and intra-abdominal abscess (>2 cm: antibiotics plus drainage, hold immunosuppression) positions are unchanged. THERAPEUTIC ENDOSCOPY (AGA Clinical Practice Update, CGH 2026; details below come from AGA news coverage, not the full text, and are ungraded advice): get cross-sectional imaging before the procedure. Endoscopic balloon dilation is first-line for short strictures (about ≤4-5 cm) with few risk factors (fistula, prestenotic dilation >5 cm, high CRP, prior anti-TNF). Longer or multiple strictures, or ≥3 risk factors, favor surgery.
Clinical takeawayConsider endoscopic stricturotomy (ES) over endoscopic balloon dilation (EBD) for short (<3 cm) Crohn's disease strictures in expert centers, as ES reduces recurrence and reintervention rates. Adverse events were similar between groups (13.2% vs 22.6%; p=0.30).
What it foundEndoscopic stricturotomy (ES) reduced 1-year clinical recurrence to 30.1% compared to 54.7% with endoscopic balloon dilation (EBD) in short Crohn's disease strictures.
ContextChallenges the current standard of EBD for short Crohn's strictures, showing ES offers superior outcomes in recurrence and reintervention rates compared to EBD.
Refinessuggested applicable standard· British Society of Gastroenterology, 'UK guidelines on oesophageal dilatation in clinical practice' (Sami SS et al., Gut 2018;67(6):1000-1023). DOI 10.1136/gutjnl-2017-315414, PMID 29478034. Achalasia-specific dilation is governed by ASGE, 'ASGE guideline on the management of achalasia' (Khashab MA et al., Gastrointest Endosc 2020;91(2):213-227.e6, DOI 10.1016/j.gie.2019.04.231, PMID 31839408).ShowHide
Widen symptomatic GI luminal strictures with mechanical bougie (Savary-Gilliard) or through-the-scope hydrostatic balloon dilation.…Treat the underlying condition first, topical steroid optimization for EoE strictures and biologic optimization for inflammatory Crohn's strictures, before or alongside dilation.…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
Widen symptomatic GI luminal strictures with mechanical bougie (Savary-Gilliard) or through-the-scope hydrostatic balloon dilation. For achalasia, use a pneumatic balloon (Rigiflex, starting at 30 mm) with graded dilation over multiple sessions to minimize perforation risk, and always biopsy to rule out malignancy at the index procedure. For non-achalasia strictures, keep the two techniques distinct rather than applying one rule to both. The 'rule of 3' is a BOUGIE (wire-guided push-dilator) rule and its trigger is tactile: once moderate resistance is felt, pass no more than 3 progressively larger dilators in roughly 1 mm (3-Fr) steps in that session. A balloon transmits no such resistance, so the rule does not transfer to it. Balloon (TTS/hydrostatic) dilation is governed instead by matching the balloon to the stricture and dilating to a pre-selected target diameter under direct endoscopic vision, with fluoroscopy added for tortuous, long or high-risk strictures; limit the first session to 10-12 mm when the stricture will not admit an adult gastroscope (9 mm or less if filiform) and repeat sessions weekly to fortnightly until easy passage of a 15 mm or larger dilator is achieved along with symptomatic improvement. BSG 2018 does advise using no more than three successively larger diameter increments in a single session for BOTH bougie and balloon dilators, but grades that advice low quality / low strength and states explicitly that the precise 3x1 mm restriction is not evidence based, 2x1 mm may be safer in very tight or long strictures and 4x1 mm or 3x2 mm may be used safely in looser strictures or ones that have completely recurred. Treat it as a ceiling to be justified, not as a technique-independent law, and do not carry the bougie resistance trigger over to balloon dilation. Treat the underlying condition first, topical steroid optimization for EoE strictures and biologic optimization for inflammatory Crohn's strictures, before or alongside dilation. For refractory benign strictures, inject intralesional triamcinolone (40 mg in 4 quadrants) and escalate to POEM/surgery or SEMS for malignant strictures as indicated.
Pal P … Reddy DN · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
IBDmeta analysis · n=2,245 · Oct 27, 2026 · Eur J Gastro Hep · IF 2.2
New evidenceulcerative colitisbiologicssystematic reviewmeta-analysis
Clinical takeawayConsider IL-23 pathway inhibitors for moderate-to-severe ulcerative colitis regardless of disease extent, but anticipate a stronger maintenance effect in extensive disease.
What it foundIL-23 inhibitors increased clinical remission compared to placebo in limited disease (RR 2.58, 95% CI 1.94-3.43) and extensive disease (RR 2.25, 95% CI 1.62-3.13) during induction, with a greater relative effect in extensive disease during maintenance (RRR 2.16, 95% CI 1.47-3.19, P < 0.001).
ContextConfirms efficacy of IL-23 inhibitors in moderate-to-severe ulcerative colitis and refines understanding of their differential maintenance effect by disease extent.
Measured against the standard of care· AGA Clinical Practice Update on Inpatient Management of Adults With IBD (Gastroenterology 2026) / ACG UC Guideline Update 2025 / AGA Living Guideline, Moderate-to-Severe UC 2024 (panel review March 2026)ShowHide
Decision at stakepositioning advanced therapy by efficacy tier in moderate-to-severe UC
Outpatient positioning is unchanged from the ACG 2025 UC guideline and the AGA living guideline for moderate-to-severe UC.…Position advanced therapy by efficacy tier, not by an anti-TNF-first rule.…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
Outpatient positioning is unchanged from the ACG 2025 UC guideline and the AGA living guideline for moderate-to-severe UC. Confirm UC with endoscopy showing continuous colonic inflammation from the rectum plus histology, after excluding infection with two-step C. difficile testing. Treat mild-moderate disease with 5-ASA chosen by route and extent: suppository for proctitis, enema for left-sided disease, oral plus rectal for extensive disease. If 5-ASA fails, treat as moderate-to-severe rather than stepping up gradually. Position advanced therapy by efficacy tier, not by an anti-TNF-first rule. Advanced-therapy-naive, higher efficacy: infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab. Intermediate: golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab. Lower: adalimumab. Previously TNF-exposed, higher efficacy: tofacitinib, upadacitinib, ustekinumab. Lower: adalimumab, vedolizumab, ozanimod, etrasimod. After anti-TNF primary non-response, switch mechanism rather than cycling within the class. Treat to target (STRIDE-II): endoscopic improvement, Mayo endoscopic subscore 0-1. Begin CRC surveillance 8-10 years after diagnosis for extensive or left-sided disease; isolated proctitis follows average-risk screening. Inpatient care now follows the 2026 AGA Clinical Practice Update (13 best-practice statements). Admit for severe symptoms refractory to outpatient therapy, suspected complications (obstruction, abscess, toxic megacolon) or significant malnutrition, and identify acute severe UC by Truelove-Witts. Give every patient admitted with diarrhea two-step C. difficile testing. Test for CMV, with early endoscopy, if symptoms worsen, the patient is systemically toxic or disease is steroid-refractory. Give routine VTE prophylaxis with LMWH or fondaparinux unless contraindicated, and individualize post-discharge extension. Give IV methylprednisolone 60 mg/day or equivalent; the AGA living guideline says 40-60 mg/day, and higher doses add no benefit. Do not give adjunctive antibiotics without infection. Involve surgery early. Assess response by day 3 (72 h) using stool frequency and CRP (Oxford criteria); do not continue IV steroids beyond about 7 days without response. Rescue steroid non-responders with infliximab (accelerated or intensified dosing in selected patients with high inflammatory burden or protein-losing colopathy), cyclosporine, or a JAK inhibitor at standard or intensified dosing, or with colectomy. Before discharge, the response should be stable and a transition plan should be in place.
New therapybiologicssystematic reviewmeta-analysis
Clinical takeawayConsider guselkumab as a treatment option for patients with moderate-to-severe ulcerative colitis or Crohn's disease, particularly those who have failed or are intolerant to other therapies, given its favorable safety profile.
What it foundGuselkumab tripled week-12 clinical remission rates (risk ratio: 2.77, 95% CI: 2.30-3.34) and halved serious adverse events (risk ratio: 0.57) versus placebo in moderate-to-severe IBD.
ContextThis meta-analysis confirms guselkumab's efficacy and safety in IBD, adding to the growing evidence for IL-23 inhibitors as a therapeutic class.
Measured against the standard of care· AGA Clinical Practice Update on Inpatient Management of Adults With IBD (Gastroenterology 2026) / ACG UC Guideline Update 2025 / AGA Living Guideline, Moderate-to-Severe UC 2024 (panel review March 2026)ShowHide
Outpatient positioning is unchanged from the ACG 2025 UC guideline and the AGA living guideline for moderate-to-severe UC.…Advanced-therapy-naive, higher efficacy: infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab.…Treat to target (STRIDE-II): endoscopic improvement, Mayo endoscopic subscore 0-1.…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
Outpatient positioning is unchanged from the ACG 2025 UC guideline and the AGA living guideline for moderate-to-severe UC. Confirm UC with endoscopy showing continuous colonic inflammation from the rectum plus histology, after excluding infection with two-step C. difficile testing. Treat mild-moderate disease with 5-ASA chosen by route and extent: suppository for proctitis, enema for left-sided disease, oral plus rectal for extensive disease. If 5-ASA fails, treat as moderate-to-severe rather than stepping up gradually. Position advanced therapy by efficacy tier, not by an anti-TNF-first rule. Advanced-therapy-naive, higher efficacy: infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab. Intermediate: golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab. Lower: adalimumab. Previously TNF-exposed, higher efficacy: tofacitinib, upadacitinib, ustekinumab. Lower: adalimumab, vedolizumab, ozanimod, etrasimod. After anti-TNF primary non-response, switch mechanism rather than cycling within the class. Treat to target (STRIDE-II): endoscopic improvement, Mayo endoscopic subscore 0-1. Begin CRC surveillance 8-10 years after diagnosis for extensive or left-sided disease; isolated proctitis follows average-risk screening. Inpatient care now follows the 2026 AGA Clinical Practice Update (13 best-practice statements). Admit for severe symptoms refractory to outpatient therapy, suspected complications (obstruction, abscess, toxic megacolon) or significant malnutrition, and identify acute severe UC by Truelove-Witts. Give every patient admitted with diarrhea two-step C. difficile testing. Test for CMV, with early endoscopy, if symptoms worsen, the patient is systemically toxic or disease is steroid-refractory. Give routine VTE prophylaxis with LMWH or fondaparinux unless contraindicated, and individualize post-discharge extension. Give IV methylprednisolone 60 mg/day or equivalent; the AGA living guideline says 40-60 mg/day, and higher doses add no benefit. Do not give adjunctive antibiotics without infection. Involve surgery early. Assess response by day 3 (72 h) using stool frequency and CRP (Oxford criteria); do not continue IV steroids beyond about 7 days without response. Rescue steroid non-responders with infliximab (accelerated or intensified dosing in selected patients with high inflammatory burden or protein-losing colopathy), cyclosporine, or a JAK inhibitor at standard or intensified dosing, or with colectomy. Before discharge, the response should be stable and a transition plan should be in place.
New evidenceulcerative colitisbiologicsJAK inhibitorsanti-TNF
Clinical takeawayRetrospective, propensity-matched data in which upadacitinib was used only after prior biologics; a positioning signal, not on its own a reason to choose ustekinumab first.
What it foundUstekinumab achieved the highest 1-year continuous clinical remission (CCR) rate in bio-naive patients, while upadacitinib had the highest CCR as second-line therapy.
ContextMulticenter cohort of 1,406 patients treated with seven advanced therapies between 2014 and 2024; ustekinumab also had the lowest adverse event rate.
Measured against the standard of care· AGA Clinical Practice Update on Inpatient Management of Adults With IBD (Gastroenterology 2026) / ACG UC Guideline Update 2025 / AGA Living Guideline, Moderate-to-Severe UC 2024 (panel review March 2026)ShowHide
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
Outpatient positioning is unchanged from the ACG 2025 UC guideline and the AGA living guideline for moderate-to-severe UC. Confirm UC with endoscopy showing continuous colonic inflammation from the rectum plus histology, after excluding infection with two-step C. difficile testing. Treat mild-moderate disease with 5-ASA chosen by route and extent: suppository for proctitis, enema for left-sided disease, oral plus rectal for extensive disease. If 5-ASA fails, treat as moderate-to-severe rather than stepping up gradually. Position advanced therapy by efficacy tier, not by an anti-TNF-first rule. Advanced-therapy-naive, higher efficacy: infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab. Intermediate: golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab. Lower: adalimumab. Previously TNF-exposed, higher efficacy: tofacitinib, upadacitinib, ustekinumab. Lower: adalimumab, vedolizumab, ozanimod, etrasimod. After anti-TNF primary non-response, switch mechanism rather than cycling within the class. Treat to target (STRIDE-II): endoscopic improvement, Mayo endoscopic subscore 0-1. Begin CRC surveillance 8-10 years after diagnosis for extensive or left-sided disease; isolated proctitis follows average-risk screening. Inpatient care now follows the 2026 AGA Clinical Practice Update (13 best-practice statements). Admit for severe symptoms refractory to outpatient therapy, suspected complications (obstruction, abscess, toxic megacolon) or significant malnutrition, and identify acute severe UC by Truelove-Witts. Give every patient admitted with diarrhea two-step C. difficile testing. Test for CMV, with early endoscopy, if symptoms worsen, the patient is systemically toxic or disease is steroid-refractory. Give routine VTE prophylaxis with LMWH or fondaparinux unless contraindicated, and individualize post-discharge extension. Give IV methylprednisolone 60 mg/day or equivalent; the AGA living guideline says 40-60 mg/day, and higher doses add no benefit. Do not give adjunctive antibiotics without infection. Involve surgery early. Assess response by day 3 (72 h) using stool frequency and CRP (Oxford criteria); do not continue IV steroids beyond about 7 days without response. Rescue steroid non-responders with infliximab (accelerated or intensified dosing in selected patients with high inflammatory burden or protein-losing colopathy), cyclosporine, or a JAK inhibitor at standard or intensified dosing, or with colectomy. Before discharge, the response should be stable and a transition plan should be in place.
New evidenceJAK inhibitorsbiologicsanti-TNFsystematic review
Clinical takeawayConsider anti-IL-12/23 or -IL-23 agents over JAK inhibitors in older patients with IMIDs due to lower serious infection risk. Monitor rheumatologic patients >60 years on JAK inhibitors for VTE risk.
What it foundJAK inhibitors increased infection risk (OR 1.38, 95% CI 1.22-1.55) and serious infection risk (OR 1.27, 1.06-1.52) in older patients with IMIDs compared to other advanced therapies, with an increased VTE risk in rheumatologic cohorts >60 years (OR 3.28, 95% CI 1.16-9.27).
ContextRefines safety data for advanced therapies in older patients, confirming higher infection risk with JAK inhibitors and identifying a potential VTE risk in rheumatologic cohorts >60 years.
Measured against the standard of care· ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH)ShowHide
No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.
Our full summary of this standardShowHide
Two current US guidelines govern Crohn's disease and should be read together. ACG 2025 (Lichtenstein et al.) remains the reference for diagnosis, mild-to-moderate disease, perianal, postoperative and abscess management. DIAGNOSIS: fecal calprotectin (>50-100 μg/g) separates inflammatory from noninflammatory disease of the colon. Workup is ileocolonoscopy with biopsies, including uninvolved mucosa, plus small-bowel imaging. CTE and MRE are comparable; prefer MRE in patients <35 y and when serial exams are likely. Intestinal ultrasound is an ungraded adjunct. Do routine CRC surveillance in Crohn's colitis. MILD-TO-MODERATE: recommend against oral mesalamine; sulfasalazine only for symptomatic mild colonic CD; ileal-release budesonide 9 mg for induction in ileocecal disease but not for maintenance. MODERATE-TO-SEVERE (AGA Living Guideline, Scott et al., Gastroenterology 2025;169(7):1397-1448, 16 recommendations: 1 strong, 9 conditional, 6 knowledge gaps; updated quarterly, adult outpatients only): RECOMMEND infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab or upadacitinib over no treatment; SUGGEST certolizumab pegol or vedolizumab over no treatment. Advanced-therapy-naive: suggest higher-efficacy agents (infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, guselkumab) over lower-efficacy ones (certolizumab pegol, upadacitinib). Prior advanced-therapy (especially anti-TNF) exposure: suggest higher- or intermediate-efficacy agents (adalimumab, risankizumab, guselkumab, upadacitinib; ustekinumab, mirikizumab) over lower-efficacy ones (vedolizumab, certolizumab pegol). Suggest against thiopurine monotherapy for induction; suggest it for maintenance of remission. Suggest SC/IM methotrexate monotherapy; suggest against oral methotrexate. In thiopurine-naive patients starting infliximab, suggest infliximab + thiopurine over infliximab alone. No recommendation on IFX + MTX, adalimumab + immunomodulator, or non-TNF biologic + immunomodulator. After ≥6 months of steroid-free remission on anti-TNF + immunomodulator, suggest withdrawing the immunomodulator and suggest against withdrawing the anti-TNF. SUGGEST upfront advanced therapy over step-up therapy (corticosteroids and/or immunomodulator first). No recommendation on treating to endoscopic vs symptomatic remission. The ACG 2025 moderate-to-severe recommendations (anti-TNF, IFX + thiopurine combination and IL-12/23/IL-23 agents, each strong/moderate; upadacitinib after anti-TNF exposure; steroids for short-term induction only; TPMT/NUDT15 testing before thiopurines) still stand alongside AGA. ACG perianal (infliximab first; drain abscesses and place setons before escalating), postoperative (endoscopy at 6-12 months; anti-TNF strong, vedolizumab conditional in high-risk patients) and intra-abdominal abscess (>2 cm: antibiotics plus drainage, hold immunosuppression) positions are unchanged. THERAPEUTIC ENDOSCOPY (AGA Clinical Practice Update, CGH 2026; details below come from AGA news coverage, not the full text, and are ungraded advice): get cross-sectional imaging before the procedure. Endoscopic balloon dilation is first-line for short strictures (about ≤4-5 cm) with few risk factors (fistula, prestenotic dilation >5 cm, high CRP, prior anti-TNF). Longer or multiple strictures, or ≥3 risk factors, favor surgery.
Le Cosquer G … Ananthakrishnan AN · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
IBDretrospective · n=560 · Oct 28, 2026 · Inflamm Bowel Dis · IF 4.5
New evidenceCrohn's diseaseJAK inhibitorsbiologicstherapeutic drug monitoring
Clinical takeawayPersistence, not efficacy, in an observational registry of mostly advanced-line patients; there was no difference in isolated colonic disease (HR 0.66).
What it foundUpadacitinib had a higher risk of discontinuation than risankizumab (HR 1.86, 95% CI 1.02-3.39), especially in patients with ileal involvement (HR 2.56, 95% CI 1.49-4.40).
ContextThis study provides real-world evidence that risankizumab may be more effective than upadacitinib in maintaining treatment persistence, particularly in advanced treatment-experienced patients with ileal Crohn's disease, refining prior limited comparative data.
Measured against the standard of care· ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH)ShowHide
Decision at stakechoosing between risankizumab and upadacitinib for Crohn's disease
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text. The rest of this standard includes DIAGNOSIS.
Our full summary of this standardShowHide
Two current US guidelines govern Crohn's disease and should be read together. ACG 2025 (Lichtenstein et al.) remains the reference for diagnosis, mild-to-moderate disease, perianal, postoperative and abscess management. DIAGNOSIS: fecal calprotectin (>50-100 μg/g) separates inflammatory from noninflammatory disease of the colon. Workup is ileocolonoscopy with biopsies, including uninvolved mucosa, plus small-bowel imaging. CTE and MRE are comparable; prefer MRE in patients <35 y and when serial exams are likely. Intestinal ultrasound is an ungraded adjunct. Do routine CRC surveillance in Crohn's colitis. MILD-TO-MODERATE: recommend against oral mesalamine; sulfasalazine only for symptomatic mild colonic CD; ileal-release budesonide 9 mg for induction in ileocecal disease but not for maintenance. MODERATE-TO-SEVERE (AGA Living Guideline, Scott et al., Gastroenterology 2025;169(7):1397-1448, 16 recommendations: 1 strong, 9 conditional, 6 knowledge gaps; updated quarterly, adult outpatients only): RECOMMEND infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab or upadacitinib over no treatment; SUGGEST certolizumab pegol or vedolizumab over no treatment. Advanced-therapy-naive: suggest higher-efficacy agents (infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, guselkumab) over lower-efficacy ones (certolizumab pegol, upadacitinib). Prior advanced-therapy (especially anti-TNF) exposure: suggest higher- or intermediate-efficacy agents (adalimumab, risankizumab, guselkumab, upadacitinib; ustekinumab, mirikizumab) over lower-efficacy ones (vedolizumab, certolizumab pegol). Suggest against thiopurine monotherapy for induction; suggest it for maintenance of remission. Suggest SC/IM methotrexate monotherapy; suggest against oral methotrexate. In thiopurine-naive patients starting infliximab, suggest infliximab + thiopurine over infliximab alone. No recommendation on IFX + MTX, adalimumab + immunomodulator, or non-TNF biologic + immunomodulator. After ≥6 months of steroid-free remission on anti-TNF + immunomodulator, suggest withdrawing the immunomodulator and suggest against withdrawing the anti-TNF. SUGGEST upfront advanced therapy over step-up therapy (corticosteroids and/or immunomodulator first). No recommendation on treating to endoscopic vs symptomatic remission. The ACG 2025 moderate-to-severe recommendations (anti-TNF, IFX + thiopurine combination and IL-12/23/IL-23 agents, each strong/moderate; upadacitinib after anti-TNF exposure; steroids for short-term induction only; TPMT/NUDT15 testing before thiopurines) still stand alongside AGA. ACG perianal (infliximab first; drain abscesses and place setons before escalating), postoperative (endoscopy at 6-12 months; anti-TNF strong, vedolizumab conditional in high-risk patients) and intra-abdominal abscess (>2 cm: antibiotics plus drainage, hold immunosuppression) positions are unchanged. THERAPEUTIC ENDOSCOPY (AGA Clinical Practice Update, CGH 2026; details below come from AGA news coverage, not the full text, and are ungraded advice): get cross-sectional imaging before the procedure. Endoscopic balloon dilation is first-line for short strictures (about ≤4-5 cm) with few risk factors (fistula, prestenotic dilation >5 cm, high CRP, prior anti-TNF). Longer or multiple strictures, or ≥3 risk factors, favor surgery.
New evidenceulcerative colitisCrohn's diseaseanti-TNFtherapeutic drug monitoring
Clinical takeawayConsider early proactive therapeutic drug monitoring in adults with ulcerative colitis who have baseline infliximab clearance > 0.28 L/day or week-6 trough ≤ 21.6 mg/L to identify high-risk subgroups unlikely to achieve remission.
What it foundBaseline infliximab clearance > 0.28 L/day and week-6 trough ≤ 21.6 mg/L identified high-risk subgroups with few remissions (0/18 and 1/20, respectively, p < 0.05) in ulcerative colitis, compared to standard infliximab therapy.
ContextThis study refines current practice by identifying specific pharmacokinetic thresholds that predict poor response to infliximab induction in ulcerative colitis, supporting a personalized approach to therapeutic drug monitoring. No robust predictors were identified in Crohn's disease.
Measured against the standard of care· AGA Clinical Practice Update on Inpatient Management of Adults With IBD (Gastroenterology 2026) / ACG UC Guideline Update 2025 / AGA Living Guideline, Moderate-to-Severe UC 2024 (panel review March 2026)ShowHide
…Advanced-therapy-naive, higher efficacy: infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab.…Test for CMV, with early endoscopy, if symptoms worsen, the patient is systemically toxic or disease is steroid-refractory.…Rescue steroid non-responders with infliximab (accelerated or intensified dosing in selected patients with high inflammatory burden or protein-losing colopathy), cyclosporine, or a JAK inhibitor at standard or intensified dosing, or with colectomy.…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
Outpatient positioning is unchanged from the ACG 2025 UC guideline and the AGA living guideline for moderate-to-severe UC. Confirm UC with endoscopy showing continuous colonic inflammation from the rectum plus histology, after excluding infection with two-step C. difficile testing. Treat mild-moderate disease with 5-ASA chosen by route and extent: suppository for proctitis, enema for left-sided disease, oral plus rectal for extensive disease. If 5-ASA fails, treat as moderate-to-severe rather than stepping up gradually. Position advanced therapy by efficacy tier, not by an anti-TNF-first rule. Advanced-therapy-naive, higher efficacy: infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab. Intermediate: golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab. Lower: adalimumab. Previously TNF-exposed, higher efficacy: tofacitinib, upadacitinib, ustekinumab. Lower: adalimumab, vedolizumab, ozanimod, etrasimod. After anti-TNF primary non-response, switch mechanism rather than cycling within the class. Treat to target (STRIDE-II): endoscopic improvement, Mayo endoscopic subscore 0-1. Begin CRC surveillance 8-10 years after diagnosis for extensive or left-sided disease; isolated proctitis follows average-risk screening. Inpatient care now follows the 2026 AGA Clinical Practice Update (13 best-practice statements). Admit for severe symptoms refractory to outpatient therapy, suspected complications (obstruction, abscess, toxic megacolon) or significant malnutrition, and identify acute severe UC by Truelove-Witts. Give every patient admitted with diarrhea two-step C. difficile testing. Test for CMV, with early endoscopy, if symptoms worsen, the patient is systemically toxic or disease is steroid-refractory. Give routine VTE prophylaxis with LMWH or fondaparinux unless contraindicated, and individualize post-discharge extension. Give IV methylprednisolone 60 mg/day or equivalent; the AGA living guideline says 40-60 mg/day, and higher doses add no benefit. Do not give adjunctive antibiotics without infection. Involve surgery early. Assess response by day 3 (72 h) using stool frequency and CRP (Oxford criteria); do not continue IV steroids beyond about 7 days without response. Rescue steroid non-responders with infliximab (accelerated or intensified dosing in selected patients with high inflammatory burden or protein-losing colopathy), cyclosporine, or a JAK inhibitor at standard or intensified dosing, or with colectomy. Before discharge, the response should be stable and a transition plan should be in place.
New evidenceCrohn's diseasediet therapybiomarkermicrobiome
Clinical takeawayConsider recommending the Tasty&Healthy diet to high-risk first-degree relatives of Crohn's disease patients with persistently elevated fecal calprotectin (>70μg/g) but no diagnostic endoscopic evidence of Crohn's disease, as it reduced median fecal calprotectin to 64μg/g compared to 112μg/g on habitual diet (P=0.022) and achieved ≥50% FC reduction in 71% vs 27% (RR=2.68, P=0.016). 79% rated T&H acceptable and 83% had good or complete adherence.
What it foundThe Tasty&Healthy diet reduced median fecal calprotectin to 64μg/g vs 112μg/g on habitual diet (P=0.022) and achieved ≥50% FC reduction in 71% vs 27% (RR=2.68, P=0.016).
ContextThis study provides early evidence that dietary intervention can modify low-grade intestinal inflammation in high-risk first-degree relatives of Crohn's disease patients with persistently elevated fecal calprotectin (>70μg/g) but no diagnostic endoscopic evidence of Crohn's disease, supporting ongoing prevention trials.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Turner D … Croitoru K · Gastroenterology · IF 25.1 · PubMed ↗Permalink
IBDprospective cohort · n=154 · Nov 1, 2026 · Inflamm Bowel Dis · IF 4.5
Clinical takeawayA single-cohort association with endoscopic healing; fecal short-chain fatty acid testing was not compared with existing markers and needs external validation.
What it foundFecal butyrate concentration was significantly higher in UC patients with mucosal healing (16.8 vs 10.2 mmol/kg, P < .001) compared to those without healing and independently predicted healing (OR 1.18, 95% CI 1.09-1.28).
ContextThis study provides new evidence linking SCFA levels, particularly butyrate, to mucosal healing in UC patients, a key therapeutic goal. It extends prior mechanistic insights into a clinical biomarker context.
Measured against the standard of care· AGA Clinical Practice Update on Inpatient Management of Adults With IBD (Gastroenterology 2026) / ACG UC Guideline Update 2025 / AGA Living Guideline, Moderate-to-Severe UC 2024 (panel review March 2026)ShowHide
Decision at stakeassessing mucosal healing in ulcerative colitis
No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.
Our full summary of this standardShowHide
Outpatient positioning is unchanged from the ACG 2025 UC guideline and the AGA living guideline for moderate-to-severe UC. Confirm UC with endoscopy showing continuous colonic inflammation from the rectum plus histology, after excluding infection with two-step C. difficile testing. Treat mild-moderate disease with 5-ASA chosen by route and extent: suppository for proctitis, enema for left-sided disease, oral plus rectal for extensive disease. If 5-ASA fails, treat as moderate-to-severe rather than stepping up gradually. Position advanced therapy by efficacy tier, not by an anti-TNF-first rule. Advanced-therapy-naive, higher efficacy: infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab. Intermediate: golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab. Lower: adalimumab. Previously TNF-exposed, higher efficacy: tofacitinib, upadacitinib, ustekinumab. Lower: adalimumab, vedolizumab, ozanimod, etrasimod. After anti-TNF primary non-response, switch mechanism rather than cycling within the class. Treat to target (STRIDE-II): endoscopic improvement, Mayo endoscopic subscore 0-1. Begin CRC surveillance 8-10 years after diagnosis for extensive or left-sided disease; isolated proctitis follows average-risk screening. Inpatient care now follows the 2026 AGA Clinical Practice Update (13 best-practice statements). Admit for severe symptoms refractory to outpatient therapy, suspected complications (obstruction, abscess, toxic megacolon) or significant malnutrition, and identify acute severe UC by Truelove-Witts. Give every patient admitted with diarrhea two-step C. difficile testing. Test for CMV, with early endoscopy, if symptoms worsen, the patient is systemically toxic or disease is steroid-refractory. Give routine VTE prophylaxis with LMWH or fondaparinux unless contraindicated, and individualize post-discharge extension. Give IV methylprednisolone 60 mg/day or equivalent; the AGA living guideline says 40-60 mg/day, and higher doses add no benefit. Do not give adjunctive antibiotics without infection. Involve surgery early. Assess response by day 3 (72 h) using stool frequency and CRP (Oxford criteria); do not continue IV steroids beyond about 7 days without response. Rescue steroid non-responders with infliximab (accelerated or intensified dosing in selected patients with high inflammatory burden or protein-losing colopathy), cyclosporine, or a JAK inhibitor at standard or intensified dosing, or with colectomy. Before discharge, the response should be stable and a transition plan should be in place.
Clinical takeawayCounsel pregnant women with IBD on the risks of obesity-related adverse pregnancy outcomes. Continue SOC preventive measures, including aspirin for those at risk and LMWH for intermediate or high VTE risk.
What it foundObesity in IBD pregnancies was independently associated with a composite adverse pregnancy outcome (OR 1.63; 95% CI 1.15-2.33), while IBD diagnosis alone showed no significant additional risk (OR 0.74; 95% CI 0.53-1.03).
ContextThis study reinforces that obesity, not IBD diagnosis alone, is a key driver of adverse pregnancy outcomes, aligning with broader evidence on obesity and pregnancy risks.
Emergingsuggested applicable standard· American Gastroenterological Association, 'Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group' (Mahadevan U et al., Gastroenterology 2019;156(5):1508-1524). DOI 10.1053/j.gastro.2018.12.022, PMID 30658060.ShowHide
In IBD patients who are pregnant or planning pregnancy, the goal remains stable steroid-free remission before conception, throughout pregnancy, and postpartum, because active disease (not medication) is the dominant driver of adverse maternal/fetal outcomes (preterm birth, growth restriction, low birth weight, hypertensive disease, cesarean birth).…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
In IBD patients who are pregnant or planning pregnancy, the goal remains stable steroid-free remission before conception, throughout pregnancy, and postpartum, because active disease (not medication) is the dominant driver of adverse maternal/fetal outcomes (preterm birth, growth restriction, low birth weight, hypertensive disease, cesarean birth). Continue effective maintenance therapy on schedule through pregnancy and lactation, mesalamine, thiopurines, and biologics/biosimilars (anti-TNF, vedolizumab, ustekinumab), rather than stopping for pregnancy; discontinuation raises postpartum flare and complication risk. SCOPE OF THE CITED SOURCE, read this before extending the sentence above: the IL-23p19 antagonists are NOT addressed by the 2019 AGA IBD Parenthood Project pathway, which predates their IBD indications entirely (Drugs@FDA efficacy-supplement approvals: risankizumab for Crohn's disease June 2022 and for ulcerative colitis June 2024; mirikizumab for ulcerative colitis October 2023 and for Crohn's disease January 2025; guselkumab for ulcerative colitis September 2024 and for Crohn's disease March 2025). Continuing risankizumab, guselkumab or mirikizumab through pregnancy and lactation is EXPERT PRACTICE extrapolated from the other monoclonal antibodies, it is not a recommendation of the cited document, and it must not be presented as one. All three FDA labels state that the available human pregnancy data are insufficient to establish a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes, and all three carry a pregnancy exposure registry: enrol the patient and document the shared decision. Avoid JAK inhibitors during pregnancy and lactation due to insufficient reproductive safety data. For suspected flare, favor fecal calprotectin plus intestinal ultrasound or non-gadolinium MRI over CT, reserve endoscopy for when it will change management, and use corticosteroids or biologic initiation/switching as clinically necessary. Recommend cesarean delivery for active perianal Crohn's disease and now also consider cesarean for patients with a prior ileal pouch-anal anastomosis (IPAA) to protect pouch function. New elements versus prior guidance: low-dose aspirin started at 12-16 weeks gestation to reduce preeclampsia risk, structured VTE risk monitoring pre-delivery and postpartum, and explicit endorsement of breastfeeding while on biologic therapy. Multidisciplinary GI/MFM coordination is maintained throughout.
New evidenceulcerative colitissystematic reviewmeta-analysisbiomarker
Clinical takeawayAcross 13 nonrandomized studies with moderate to high heterogeneity, isolated PARP was linked to proctitis but not to progression, treatment escalation or colectomy, so it need not by itself be read as more extensive or severe disease.
What it foundPeriappendiceal red patch (PARP) in UC is associated with higher odds of proctitis (OR 1.54, 95% CI 1.09-2.18) but does not increase risk of disease progression, medication escalation, or colectomy.
ContextChallenges prior assumptions that PARP indicates severe disease or worse outcomes, confirming it as a benign endoscopic finding.
Measured against the standard of care· AGA Clinical Practice Update on Inpatient Management of Adults With IBD (Gastroenterology 2026) / ACG UC Guideline Update 2025 / AGA Living Guideline, Moderate-to-Severe UC 2024 (panel review March 2026)ShowHide
…Confirm UC with endoscopy showing continuous colonic inflammation from the rectum plus histology, after excluding infection with two-step C. difficile testing. Treat mild-moderate disease with 5-ASA chosen by route and extent: suppository for proctitis, enema for left-sided disease, oral plus rectal for extensive disease.…Begin CRC surveillance 8-10 years after diagnosis for extensive or left-sided disease; isolated proctitis follows average-risk screening.…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
Outpatient positioning is unchanged from the ACG 2025 UC guideline and the AGA living guideline for moderate-to-severe UC. Confirm UC with endoscopy showing continuous colonic inflammation from the rectum plus histology, after excluding infection with two-step C. difficile testing. Treat mild-moderate disease with 5-ASA chosen by route and extent: suppository for proctitis, enema for left-sided disease, oral plus rectal for extensive disease. If 5-ASA fails, treat as moderate-to-severe rather than stepping up gradually. Position advanced therapy by efficacy tier, not by an anti-TNF-first rule. Advanced-therapy-naive, higher efficacy: infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab. Intermediate: golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab. Lower: adalimumab. Previously TNF-exposed, higher efficacy: tofacitinib, upadacitinib, ustekinumab. Lower: adalimumab, vedolizumab, ozanimod, etrasimod. After anti-TNF primary non-response, switch mechanism rather than cycling within the class. Treat to target (STRIDE-II): endoscopic improvement, Mayo endoscopic subscore 0-1. Begin CRC surveillance 8-10 years after diagnosis for extensive or left-sided disease; isolated proctitis follows average-risk screening. Inpatient care now follows the 2026 AGA Clinical Practice Update (13 best-practice statements). Admit for severe symptoms refractory to outpatient therapy, suspected complications (obstruction, abscess, toxic megacolon) or significant malnutrition, and identify acute severe UC by Truelove-Witts. Give every patient admitted with diarrhea two-step C. difficile testing. Test for CMV, with early endoscopy, if symptoms worsen, the patient is systemically toxic or disease is steroid-refractory. Give routine VTE prophylaxis with LMWH or fondaparinux unless contraindicated, and individualize post-discharge extension. Give IV methylprednisolone 60 mg/day or equivalent; the AGA living guideline says 40-60 mg/day, and higher doses add no benefit. Do not give adjunctive antibiotics without infection. Involve surgery early. Assess response by day 3 (72 h) using stool frequency and CRP (Oxford criteria); do not continue IV steroids beyond about 7 days without response. Rescue steroid non-responders with infliximab (accelerated or intensified dosing in selected patients with high inflammatory burden or protein-losing colopathy), cyclosporine, or a JAK inhibitor at standard or intensified dosing, or with colectomy. Before discharge, the response should be stable and a transition plan should be in place.
Clinical takeawayRetrospective evidence suggests histologic normalization may be a potential treatment target in MC, particularly for symptomatic patients, to reduce corticosteroid use. Further studies are needed to confirm this as a clinical goal.
What it foundHistologic normalization at first repeat colonoscopy reduced corticosteroid use (OR 0.26; 0.13-0.53) compared to patients with persistent MC changes, especially symptomatic ones (OR 0.22; 0.08-0.59), though the effect was weaker in asymptomatic patients (OR 0.45; 0.16-1.29).
ContextChallenges the lack of consensus on treatment goals in MC by suggesting histologic remission as a potential target to reduce corticosteroid use, based on retrospective cohort data.
Emergingsuggested applicable standard· United European Gastroenterology (UEG) & European Microscopic Colitis Group (EMCG), "European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations" (Miehlke et al.), 2021, Recommendation 1.8ShowHide
Decision at stakewhether histologic normalization should be a treatment target in microscopic colitis
Diagnose microscopic colitis on colonoscopy with biopsies from at least two colonic segments (proximal/ascending and distal/descending, ~3 biopsies per segment in separate jars, avoiding rectum-only sampling since it can miss >20% of cases), plus celiac serology (tTG-IgA) and an infectious workup before treatment.…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
Diagnose microscopic colitis on colonoscopy with biopsies from at least two colonic segments (proximal/ascending and distal/descending, ~3 biopsies per segment in separate jars, avoiding rectum-only sampling since it can miss >20% of cases), plus celiac serology (tTG-IgA) and an infectious workup before treatment. First step is withdrawal of implicated drugs (PPIs, NSAIDs, SSRIs, and other suspected culprits such as statins/ARBs), but only for agents with a suspected chronological (temporal) relationship between drug introduction and onset of diarrhea, and only when discontinuation is clinically safe and an appropriate alternative exists, rather than reflexive class-wide withdrawal (the European UEG/EMCG guideline suggests considering withdrawal of any drug with such a temporal relationship, and notes PPI-switch data contradict a strict class effect), together with smoking-cessation counseling. For symptomatic disease, AGA's guideline recommends budesonide 9 mg once daily for 6-8 weeks as induction, preferred over mesalamine (budesonide gave nearly double the remission rate in head-to-head RCTs); when budesonide is not feasible AGA suggests mesalamine, bismuth subsalicylate, or prednisone/prednisolone as second-line alternatives, the European UEG/EMCG guideline is stricter and recommends against mesalamine outright (not superior to placebo in trials). Maintenance uses budesonide tapered to the lowest effective dose (typically 4.5-6 mg/day) individualized to the patient, since roughly 80% relapse after stopping. Budesonide non-/partial responders should be evaluated for bile acid diarrhea (cholestyramine trial can reduce budesonide dependence), celiac disease, and SIBO before escalating refractory disease to thiopurines (azathioprine/6-MP) or biologics (anti-TNF, vedolizumab).
Clinical takeawayAsk about sleep in IBD, particularly with active disease, stress or anxiety. Only 0.5% had used cognitive behavioral therapy for insomnia; patients were most interested in wearable monitoring, home-based testing, and behavioral and light-based therapies.
What it found76.5% of adults with Crohn disease and ulcerative colitis reported poor sleep quality, and 55.9% had clinically significant sleep disturbance, which was more common in active disease than remission (80.9% vs 46.0%, P < .001).
ContextConfirms the high prevalence of sleep disturbances in adults with Crohn disease and ulcerative colitis and identifies key associated factors, highlighting a gap in the use of evidence-based therapies.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Said H … Hirten RP · Inflammatory Bowel Diseases · IF 4.5 · PubMed ↗Permalink
IBDretrospective · n=3,698 · Oct 30, 2026 · Eur J Gastro Hep · IF 2.2
New evidenceepidemiologyCrohn's diseaseulcerative colitis
Clinical takeawayAnemia stays common years after diagnosis, especially in women and complex phenotypes, though rates were lower after 2010; the registry does not define a monitoring interval.
What it foundAnemia prevalence in IBD patients was 57% in women and 55% in men at diagnosis, decreasing to 35% in women and 20% in men 5 years post-diagnosis, with significantly lower prevalence in patients diagnosed after 2010 compared to those diagnosed before 2010.
ContextConfirms anemia as a common complication in adults with IBD, with higher prevalence in women and complex phenotypes, and shows a decline over time but persistent burden, particularly in patients diagnosed before 2010.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Ismail A … Af Björkesten CG · European Journal of Gastroenterology & Hepatology · IF 2.2 · PubMed ↗Permalink
IBDretrospective · n=157,737 · Nov 1, 2026 · Inflamm Bowel Dis · IF 4.5
New evidenceepidemiologybiologicsJAK inhibitorsanti-TNF
Clinical takeawayReassure IBD patients that RSV risk and outcomes are comparable to non-IBD patients, and continue current RSV vaccination recommendations.
What it foundRSV incidence was similar in IBD and non-IBD patients (219 vs 426 cases), with hospitalization rates of 18.26% vs 13.15% (P=0.08).
ContextConfirms prior evidence that IBD does not increase RSV risk or severity, even across medication classes.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Khan N … Farraye FA · Inflammatory Bowel Diseases · IF 4.5 · PubMed ↗Permalink
Clinical takeawayNo clinical action yet: a mechanistic review of somatic mutations in chronic enteropathies. Consider mutation profiling in refractory coeliac disease for future risk stratification and therapeutic strategies, but current evidence does not support routine testing.
What it foundSomatic mutations in expanded intraepithelial lymphocyte clones are implicated in refractory coeliac disease (types I and II) and other enteropathies, with potential links to lymphoma.
ContextThis review refines understanding of chronic enteropathies by linking somatic mutations to clonal expansion and disease progression, particularly in refractory coeliac disease, challenging the traditional view of these conditions as purely inflammatory.
Measured against the standard of care· ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH)ShowHide
No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.
Our full summary of this standardShowHide
Two current US guidelines govern Crohn's disease and should be read together. ACG 2025 (Lichtenstein et al.) remains the reference for diagnosis, mild-to-moderate disease, perianal, postoperative and abscess management. DIAGNOSIS: fecal calprotectin (>50-100 μg/g) separates inflammatory from noninflammatory disease of the colon. Workup is ileocolonoscopy with biopsies, including uninvolved mucosa, plus small-bowel imaging. CTE and MRE are comparable; prefer MRE in patients <35 y and when serial exams are likely. Intestinal ultrasound is an ungraded adjunct. Do routine CRC surveillance in Crohn's colitis. MILD-TO-MODERATE: recommend against oral mesalamine; sulfasalazine only for symptomatic mild colonic CD; ileal-release budesonide 9 mg for induction in ileocecal disease but not for maintenance. MODERATE-TO-SEVERE (AGA Living Guideline, Scott et al., Gastroenterology 2025;169(7):1397-1448, 16 recommendations: 1 strong, 9 conditional, 6 knowledge gaps; updated quarterly, adult outpatients only): RECOMMEND infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab or upadacitinib over no treatment; SUGGEST certolizumab pegol or vedolizumab over no treatment. Advanced-therapy-naive: suggest higher-efficacy agents (infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, guselkumab) over lower-efficacy ones (certolizumab pegol, upadacitinib). Prior advanced-therapy (especially anti-TNF) exposure: suggest higher- or intermediate-efficacy agents (adalimumab, risankizumab, guselkumab, upadacitinib; ustekinumab, mirikizumab) over lower-efficacy ones (vedolizumab, certolizumab pegol). Suggest against thiopurine monotherapy for induction; suggest it for maintenance of remission. Suggest SC/IM methotrexate monotherapy; suggest against oral methotrexate. In thiopurine-naive patients starting infliximab, suggest infliximab + thiopurine over infliximab alone. No recommendation on IFX + MTX, adalimumab + immunomodulator, or non-TNF biologic + immunomodulator. After ≥6 months of steroid-free remission on anti-TNF + immunomodulator, suggest withdrawing the immunomodulator and suggest against withdrawing the anti-TNF. SUGGEST upfront advanced therapy over step-up therapy (corticosteroids and/or immunomodulator first). No recommendation on treating to endoscopic vs symptomatic remission. The ACG 2025 moderate-to-severe recommendations (anti-TNF, IFX + thiopurine combination and IL-12/23/IL-23 agents, each strong/moderate; upadacitinib after anti-TNF exposure; steroids for short-term induction only; TPMT/NUDT15 testing before thiopurines) still stand alongside AGA. ACG perianal (infliximab first; drain abscesses and place setons before escalating), postoperative (endoscopy at 6-12 months; anti-TNF strong, vedolizumab conditional in high-risk patients) and intra-abdominal abscess (>2 cm: antibiotics plus drainage, hold immunosuppression) positions are unchanged. THERAPEUTIC ENDOSCOPY (AGA Clinical Practice Update, CGH 2026; details below come from AGA news coverage, not the full text, and are ungraded advice): get cross-sectional imaging before the procedure. Endoscopic balloon dilation is first-line for short strictures (about ≤4-5 cm) with few risk factors (fistula, prestenotic dilation >5 cm, high CRP, prior anti-TNF). Longer or multiple strictures, or ≥3 risk factors, favor surgery.
Singh M … Luciani F · Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · IF 4.2 · PubMed ↗Permalink
IBDprospective cohort · n=32 · Oct 30, 2026 · J Neurogastro Motil · IF 3.4
Clinical takeawayA small exploratory signal that strictures may mask SIBO on breath testing; it does not show that retesting changes management.
What it foundHydrogen-type SIBO (H-SIBO) was detected in 18.8% of Crohn's disease patients after stricture-directed interventions (6/32), compared to 9.4% pre-intervention (3/32) and 0% in healthy controls (0/33), using the North American Consensus criteria.
ContextThis study suggests that small-bowel strictures may mask SIBO detection and that interventions can uncover it, refining prior understanding of SIBO prevalence in Crohn's disease. However, findings should be interpreted with caution given the study's limitations.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Igarashi T … Terai S · Journal of Neurogastroenterology and Motility · IF 3.4 · PubMed ↗Permalink